{"id":201230,"date":"2026-11-08T21:52:11","date_gmt":"2026-11-08T21:52:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/201230\/"},"modified":"2026-11-08T21:52:11","modified_gmt":"2026-11-08T21:52:11","slug":"amgens-maritide-aims-to-cut-obesity-shots-from-52-a-year-to-as-few-as-four-biggo-finance","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/201230\/","title":{"rendered":"Amgen&#8217;s MariTide Aims to Cut Obesity Shots From 52 a Year to as Few as Four \u2014 BigGo Finance"},"content":{"rendered":"<p>Amgen is betting that convenience, not raw weight loss, can carve it a place in the crowded obesity drug market. The Thousand Oaks, California-based company is developing MariTide, an experimental therapy designed to be injected once a month, or potentially once every three months, instead of the weekly schedule that defines the current standard of care.<\/p>\n<p>That difference is not trivial. Patients on Novo Nordisk&#8217;s Wegovy or Eli Lilly&#8217;s Zepbound face 52 injections a year. If MariTide clears late-stage testing, that burden could fall to as few as 12 or even four shots annually.<\/p>\n<p>The company said it began a Phase 3 trial in the third quarter that pits MariTide head-to-head against Novo Nordisk&#8217;s semaglutide, the active ingredient in Wegovy. Enrollment is also complete for two sleep apnea studies and a cardiovascular outcomes trial, and a first Phase 3 Type 2 diabetes study comparing MariTide with semaglutide is now recruiting. Two additional diabetes trials are slated to begin before the end of 2026.<\/p>\n<p>&#8220;We delivered another strong quarter,&#8221; Chief Executive Robert Bradway said on the company&#8217;s earnings call, during which Amgen also lifted its full-year outlook.<\/p>\n<p>A market built around weekly injections<\/p>\n<p>Eli Lilly and Novo Nordisk currently dominate the category, and both rely on once-weekly dosing. That routine is a known weak point: a study published in the Journal of Managed Care Pharmacy found many patients abandon the drugs within a year, citing side effects, cost and the hassle of frequent injections. Amgen argues a monthly option could help patients who struggle with adherence, as well as those who live far from a pharmacy or travel frequently for work.<\/p>\n<p>The commercial logic is straightforward, but the clinical bar is high. MariTide&#8217;s Phase 2 data showed roughly 20% average weight loss over a year, short of Zepbound&#8217;s results and well below the 28% reported for Lilly&#8217;s experimental candidate retatrutide. Truist Securities wrote earlier this year that MariTide &#8220;remains the focal point&#8221; for Amgen, while cautioning that its real-world value hinges on whether less frequent dosing holds up over long-term use.<\/p>\n<p>Third-quarter results and pipeline dependence<\/p>\n<p>Amgen&#8217;s third-quarter revenue climbed 8% to $10.4 billion, while non-GAAP earnings per share rose 14% to $6.45, topping the $5.79 consensus compiled by LSEG. The company raised its full-year adjusted earnings guidance to a range of $22.90 to $23.70 per share.<\/p>\n<p>MetricQ3 resultComparisonRevenue$10.4 billionUp 8% year over yearNon-GAAP EPS$6.45Up 14%; consensus $5.79Full-year adjusted EPS guidance$22.90-$23.70RaisedRepatha sales$1.08 billionUp 37%UPLIZNA sales$451 millionUp 191%IMDELLTRA sales$406 millionUp 128%<\/p>\n<p>Note: Consensus figure from LSEG data.<\/p>\n<p>The quarter&#8217;s standout performers were the cholesterol drug Repatha, the rare autoimmune disease medicine UPLIZNA and the lung cancer therapy IMDELLTRA. Amgen already has 17 products on track to generate more than $1 billion in annual sales each, giving it a commercial base that does not depend on the obesity bet.<\/p>\n<p>Even so, the stock&#8217;s next leg higher is tied closely to MariTide. Phase 3 readouts are expected in 2027, and if the results mirror Phase 2, Amgen may struggle to close the efficacy gap with Lilly and Novo Nordisk on weight loss alone.<\/p>\n<p>What it means for investors<\/p>\n<p>The stakes are large. Goldman Sachs expects the obesity market to reach $114 billion by 2030, and a monthly or quarterly injection could capture patients who currently avoid or abandon weekly therapy. Rivals are moving in the same direction: Pfizer has 10 late-stage weight-loss trials underway, including a monthly-shot program that produced 12% weight reduction in recent studies.<\/p>\n<p>For Amgen, the setup is asymmetric. A diversified portfolio of marketed drugs cushions the downside, but the upside case rests almost entirely on whether MariTide can deliver competitive weight loss with a dosing schedule patients find easier to live with.<\/p>\n","protected":false},"excerpt":{"rendered":"Amgen is betting that convenience, not raw weight loss, can carve it a place in the crowded obesity&hellip;\n","protected":false},"author":2,"featured_media":201231,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[20763,276,16213,89403,74908,272,89401,16768,89399,689,89400,89402,1910,3103],"class_list":["post-201230","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-amgen","tag-eli-lilly","tag-goldman-sachs","tag-imdelltra","tag-maritide","tag-novo-nordisk","tag-repatha","tag-retatrutide","tag-robert-bradway","tag-semaglutide","tag-truist-securities","tag-uplizna","tag-wegovy","tag-zepbound"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117583042693490384","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/201230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=201230"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/201230\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/201231"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=201230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=201230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=201230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}